Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer

Hong Zheng, Xin Liu, Jianhong Zhang, Shawn J. Rice, Matthias Wagman, Yaxian Kong, Liuluan Zhu, Junjia Zhu, Monika Joshi, Chandra Belani

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Recent success of using agents inhibiting the major immune check point, programmed cell death-1 (PD-1) pathway, offers a great promise for effective cancer therapy. Two blocking antibodies for PD-1, nivolumab and pembrolizumab have recently been approved for treating advanced recurrent non-small cell lung cancer (NSCLC). Activation of PD-1 on T cells and PD-L1 on tumor cells or antigen presenting cells leads to T cell exhaustion and ultimately tumor growth. In this study, we performed flow cytometry analysis of peripheral blood samples collected from patients with advanced NSCLC at initial diagnosis. We report that surface expression of PD-1 on CD4+ T cells has a prognostic value in NSCLC patients, as high expression of PD-1 is associated with a shorter progression-free survival and overall survival. Importantly, we also found that high PD-1 expression on peripheral CD4+ T cells is associated with inferior clinical response in a subset of patients who received anti-PD-L1 treatment, indicating a potential predictive value of this marker. This work highlights the potential of a non-invasive and effective method to determine prognostic and predictive biomarkers for inhibiting the PD-1 pathway in NSCLC patients.

Original languageEnglish (US)
Pages (from-to)56233-56240
Number of pages8
JournalOncotarget
Volume7
Issue number35
DOIs
StatePublished - Jan 1 2016

Fingerprint

Non-Small Cell Lung Carcinoma
Cell Death
T-Lymphocytes
Neoplasms
Blocking Antibodies
Antigen-Presenting Cells
Disease-Free Survival
Flow Cytometry
Biomarkers
Survival
Therapeutics
Growth

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

Zheng, Hong ; Liu, Xin ; Zhang, Jianhong ; Rice, Shawn J. ; Wagman, Matthias ; Kong, Yaxian ; Zhu, Liuluan ; Zhu, Junjia ; Joshi, Monika ; Belani, Chandra. / Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. In: Oncotarget. 2016 ; Vol. 7, No. 35. pp. 56233-56240.
@article{319e23f90c8c4670b89e36f1992c2374,
title = "Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer",
abstract = "Recent success of using agents inhibiting the major immune check point, programmed cell death-1 (PD-1) pathway, offers a great promise for effective cancer therapy. Two blocking antibodies for PD-1, nivolumab and pembrolizumab have recently been approved for treating advanced recurrent non-small cell lung cancer (NSCLC). Activation of PD-1 on T cells and PD-L1 on tumor cells or antigen presenting cells leads to T cell exhaustion and ultimately tumor growth. In this study, we performed flow cytometry analysis of peripheral blood samples collected from patients with advanced NSCLC at initial diagnosis. We report that surface expression of PD-1 on CD4+ T cells has a prognostic value in NSCLC patients, as high expression of PD-1 is associated with a shorter progression-free survival and overall survival. Importantly, we also found that high PD-1 expression on peripheral CD4+ T cells is associated with inferior clinical response in a subset of patients who received anti-PD-L1 treatment, indicating a potential predictive value of this marker. This work highlights the potential of a non-invasive and effective method to determine prognostic and predictive biomarkers for inhibiting the PD-1 pathway in NSCLC patients.",
author = "Hong Zheng and Xin Liu and Jianhong Zhang and Rice, {Shawn J.} and Matthias Wagman and Yaxian Kong and Liuluan Zhu and Junjia Zhu and Monika Joshi and Chandra Belani",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.9316",
language = "English (US)",
volume = "7",
pages = "56233--56240",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "35",

}

Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer. / Zheng, Hong; Liu, Xin; Zhang, Jianhong; Rice, Shawn J.; Wagman, Matthias; Kong, Yaxian; Zhu, Liuluan; Zhu, Junjia; Joshi, Monika; Belani, Chandra.

In: Oncotarget, Vol. 7, No. 35, 01.01.2016, p. 56233-56240.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Expression of PD-1 on CD4+ T cells in peripheral blood associates with poor clinical outcome in non-small cell lung cancer

AU - Zheng, Hong

AU - Liu, Xin

AU - Zhang, Jianhong

AU - Rice, Shawn J.

AU - Wagman, Matthias

AU - Kong, Yaxian

AU - Zhu, Liuluan

AU - Zhu, Junjia

AU - Joshi, Monika

AU - Belani, Chandra

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Recent success of using agents inhibiting the major immune check point, programmed cell death-1 (PD-1) pathway, offers a great promise for effective cancer therapy. Two blocking antibodies for PD-1, nivolumab and pembrolizumab have recently been approved for treating advanced recurrent non-small cell lung cancer (NSCLC). Activation of PD-1 on T cells and PD-L1 on tumor cells or antigen presenting cells leads to T cell exhaustion and ultimately tumor growth. In this study, we performed flow cytometry analysis of peripheral blood samples collected from patients with advanced NSCLC at initial diagnosis. We report that surface expression of PD-1 on CD4+ T cells has a prognostic value in NSCLC patients, as high expression of PD-1 is associated with a shorter progression-free survival and overall survival. Importantly, we also found that high PD-1 expression on peripheral CD4+ T cells is associated with inferior clinical response in a subset of patients who received anti-PD-L1 treatment, indicating a potential predictive value of this marker. This work highlights the potential of a non-invasive and effective method to determine prognostic and predictive biomarkers for inhibiting the PD-1 pathway in NSCLC patients.

AB - Recent success of using agents inhibiting the major immune check point, programmed cell death-1 (PD-1) pathway, offers a great promise for effective cancer therapy. Two blocking antibodies for PD-1, nivolumab and pembrolizumab have recently been approved for treating advanced recurrent non-small cell lung cancer (NSCLC). Activation of PD-1 on T cells and PD-L1 on tumor cells or antigen presenting cells leads to T cell exhaustion and ultimately tumor growth. In this study, we performed flow cytometry analysis of peripheral blood samples collected from patients with advanced NSCLC at initial diagnosis. We report that surface expression of PD-1 on CD4+ T cells has a prognostic value in NSCLC patients, as high expression of PD-1 is associated with a shorter progression-free survival and overall survival. Importantly, we also found that high PD-1 expression on peripheral CD4+ T cells is associated with inferior clinical response in a subset of patients who received anti-PD-L1 treatment, indicating a potential predictive value of this marker. This work highlights the potential of a non-invasive and effective method to determine prognostic and predictive biomarkers for inhibiting the PD-1 pathway in NSCLC patients.

UR - http://www.scopus.com/inward/record.url?scp=84984924403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984924403&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.9316

DO - 10.18632/oncotarget.9316

M3 - Article

C2 - 27191652

AN - SCOPUS:84984924403

VL - 7

SP - 56233

EP - 56240

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 35

ER -